RESUMEN
BACKGROUND AND OBJECTIVE: A bias in clinical investigations on gastrointestinal lymphomas is the lack of testing the intention to treat as to resection, emergency conditions at presentation and selection brought about by the evaluation of feasibility of surgery. DESIGN AND METHODS: A prospective study involved 154 patients with gastrointestinal nodular or high-grade MALT lymphomas, 111 with a gastric and 43 with an intestinal presentation. The decision to resect or treat conservatively was left to clinicians, on condition that it was previously defined for each patient. RESULTS: Failure-free survival was significantly higher in the 106 resected patients than in the 48 unresected ones but did not differ according to either primary intention to treat or emergency surgery/elective treatment. Survival was similar in patients operated on by choice and in those because of an emergency. Intentionally unresected patients had a significantly better survival than those not undergoing surgery despite the initial intention, for a number of clinical reasons. Patients with gastric lymphoma survived longer than those with intestinal disease and prognostic factors were analyzed separately in the two groups. The best predictors of prognosis were performance status and serum lactic dehydrogenase level in gastric lymphomas, resection alone in intestinal ones. INTERPRETATION AND CONCLUSIONS: The prognosis of gastric lymphomas depends on lymphoma-related factors and not on surgical treatment. The prognosis of intestinal ones is exclusively related to surgery. These data support the appropriateness of different clinical approaches to gastric and intestinal lymphomas.
Asunto(s)
Neoplasias Gastrointestinales/cirugía , Linfoma de Células B de la Zona Marginal/cirugía , Linfoma/cirugía , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Supervivencia sin Enfermedad , Femenino , Neoplasias Gastrointestinales/terapia , Humanos , Linfoma/patología , Linfoma/terapia , Linfoma de Células B de la Zona Marginal/patología , Linfoma de Células B de la Zona Marginal/terapia , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Estadística como Asunto , Tasa de SupervivenciaRESUMEN
The influence of extrahepatic neoplastic disease on the biotransformation of theophylline was assessed by comparing the pharmacokinetic and metabolic profile of the drug in six patients with advanced breast or bronchial carcinoma, without detectable liver metastases, and in six appropriately matched control subjects. Each subject was given a single dose of theophylline (5 mg/kg) in oral solution; blood and urinary samples were collected for up to 24 h after dosing. Theophylline was absorbed rapidly in all subjects and within 2 h reached comparable peak concentrations in both groups (cancer patients: 57.8 +/- 14.4 mumol/l; controls; 65.0 +/- 10.6 mumol/l; N.S., means +/- s.d.). No significant differences were observed between cancer patients and controls for theophylline apparent volume of distribution (0.44 +/- 0.07 vs 0.40 +/- 0.06 l/kg), total body clearance (40.8 +/- 12.8 vs 34.8 +/- 13.0 ml kg-1 h-1) and elimination half-life (8.0 +/- 1.6 vs 8.5 +/- 1.8 h). The excretion of the major metabolites 3-methyl-xanthine and 1,3-dimethyl-uric acid was also very similar in the two groups. These data do not provide any evidence for an altered rate or pattern of theophylline biotransformation in patients with advanced extrahepatic neoplastic disease.
Asunto(s)
Neoplasias de la Mama/metabolismo , Neoplasias Pulmonares/metabolismo , Teofilina/farmacocinética , Adulto , Biotransformación , Neoplasias de la Mama/complicaciones , Femenino , Semivida , Humanos , Técnicas para Inmunoenzimas , Absorción Intestinal , Neoplasias Hepáticas/secundario , Neoplasias Pulmonares/complicaciones , Masculino , Persona de Mediana Edad , Teofilina/sangre , Teofilina/orinaRESUMEN
Rufloxacin is a new long-acting, once-daily quinolone antibacterial agent. We evaluated inter- and intrasubject variations in pharmacokinetics of rufloxacin following oral administration of 400 mg (two capsules) under controlled conditions, at an interval of 2 weeks (periods I and II), to 12 healthy male subjects. Plasma and urine samples were collected up to 48 h after drug administration. Plasma drug levels determined by bioassay were higher than those measured by high-performance liquid chromatography, indicating that one or more active metabolites were formed. Individual high-performance liquid chromatography plasma rufloxacin concentrations were fitted with a one-compartment open model with first-order input. There were considerable variations in the plasma concentration-time profiles among subjects; for example, the elimination half-life in plasma varied from 14.6 to 95.5 h. However, pharmacokinetic parameters calculated for the two periods did not differ significantly. These results suggest that the intrasubject variation in the pharmacokinetics of rufloxacin is usually small in spite of the considerable intersubject variation.
Asunto(s)
Antiinfecciosos/farmacocinética , Fluoroquinolonas , Quinolonas , 4-Quinolonas , Adulto , Antiinfecciosos/administración & dosificación , Cromatografía Líquida de Alta Presión , Semivida , Humanos , Individualidad , Masculino , Pruebas de Sensibilidad Microbiana , Modelos Biológicos , Espectrofotometría UltravioletaRESUMEN
The pharmacokinetic profile of an innovative formulation of soluble aspirin (l-ornithine acetylsalicylate, ldB 1003) was compared with that of conventional tablets and two other soluble dosage forms (d, l-lysine acetylsalicylate and a buffered effervescent formulation of acetylsalicylic acid) after administration of single oral doses in six normal volunteers. All soluble forms showed a rapid absorption profile, peak plasma salicylic acid levels being attained after about 30 min on average and without statistically significant differences among the solutions tested. As compared to the soluble formulations, acetylsalicylic acid given as tablets resulted in slower absorption, with peak plasma salicylic acid levels being reached more than 1 h after dosing. Despite these differences in time course of plasma level profiles, the extent of absorption was similar for all formulations. Apart from the potential advantages in terms of improved gastric tolerability, the increased rate of absorption of aspirin solutions is therapeutically useful whenever a rapid onset of action is required. In this respect, the kinetic pattern of the innovative formulation compares favourably with that of other available soluble dosage forms.
Asunto(s)
Aspirina/farmacocinética , Salicilatos/farmacocinética , Adulto , Aspirina/administración & dosificación , Aspirina/análogos & derivados , Tampones (Química) , Humanos , Lisina/análogos & derivados , Lisina/farmacocinética , Salicilatos/sangre , Ácido Salicílico , Solubilidad , ComprimidosRESUMEN
The control of myeloma bone disease has been an important therapeutic problem. Bisphosphonates are potentially active for the control of myeloma bone resorption. Although several studies proved the efficacy of short-term bisphosphonate treatment in inhibiting myeloma bone destruction, data on the long-term efficacy are scanty. We present the results of a prospective pilot study for the evaluation of long-term parenteral administration of dichloromethylene bisphosphonate (Clodronate) in 30 patients with active myeloma bone disease. Patients were treated with a mean of 4 courses (range 2-8) of Clodronate: 300 mg/d i.v. for 7 days followed by 100 mg/d i.m. for 10 d, administered at a mean interval of 4 months. The median follow-up was 24 months (range 8-36). Clodronate reduced bone pain rapidly and significantly, and reduced the mean values of the biochemical indices of bone resorption to within normal limits. The occurrence of skeletal morbidity in patients treated with Clodronate was compared with that observed in the control group of myeloma patients treated with chemotherapy only: Clodronate provided a significant (p less than 0.001) reduction in severe bone pain as well as in the incidence of new osteolytic lesions and pathological fractures. The results of this prospective pilot trial indicate that supportive long-term treatment with parenteral Clodronate can contribute significantly to controlling the progression of myeloma bone disease.
Asunto(s)
Enfermedades Óseas/complicaciones , Ácido Clodrónico/uso terapéutico , Difosfonatos/uso terapéutico , Hipercalcemia/tratamiento farmacológico , Mieloma Múltiple/complicaciones , Dolor/tratamiento farmacológico , Enfermedades Óseas/tratamiento farmacológico , Evaluación de Medicamentos , Humanos , Hipercalcemia/etiología , Dolor/etiología , Proyectos PilotoAsunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica , Difosfonatos/administración & dosificación , Quimioterapia Combinada , Mieloma Múltiple/tratamiento farmacológico , Alendronato , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Femenino , Humanos , Melfalán/administración & dosificación , Persona de Mediana Edad , Mieloma Múltiple/mortalidad , Prednisona/administración & dosificación , Vincristina/administración & dosificaciónRESUMEN
The serum protein binding of valproic acid (VPA) and phenytoin (PHT) was determined in spiked serum samples collected from 17 patients with insulin-dependent diabetes mellitus and 16 healthy control subjects. The free fraction of VPA was significantly greater in patients than in controls (7.6 +/- 1.6% vs. 6.2 +/- 1.2%, p less than 0.01); for PHT, free fraction values were similar in the two groups (8.2 +/- 1.1% vs. 8.4 +/- 1.2%). The free fraction of VPA in diabetic patients was positively correlated with free fatty acid (FFA) concentration (r = 0.79, p less than 0.01). No significant relationships could be found between free drug fraction and either serum albumin or glycosylated protein concentration.
Asunto(s)
Proteínas Sanguíneas/metabolismo , Diabetes Mellitus Tipo 1/sangre , Fenitoína/sangre , Ácido Valproico/sangre , Adolescente , Adulto , Ácidos Grasos no Esterificados/sangre , Femenino , Glicosilación , Humanos , Masculino , Persona de Mediana Edad , Albúmina Sérica/análisisRESUMEN
We have compared in an open trial the clinical and biochemical effects of a new aminodiphosphonate, aminohydroxybutylidene diphosphonate, with those of dichloromethylene diphosphonate, which has been proved effective. The patients presented extensive and symptomatic bone involvement from multiple myeloma, breast cancer, and other metastatic tumors. The treatment consisted of aminohydroxybutylidene diphosphonate, 2.5 mg/d intravenously for five days, or dichloromethylene diphosphonate, 300 mg/d intravenously for seven days, followed by 100 mg/d intramuscularly for ten days. Twelve patients treated with aminohydroxybutylidene diphosphonate and 16 patients treated with dichloromethylene diphosphonate were assessable and were followed up for one to six months. Therapy with aminohydroxybutylidene diphosphonate showed a quicker action in reducing bone pain and reduced significantly more the serum calcium level than did therapy with dichloromethylene diphosphonate. Aminohydroxybutylidene diphosphonate therapy also affected urinary calcium levels and hydroxyproline excretion more markedly than did dichloromethylene diphosphonate, although the differences are not statistically significant. However, the biochemical indexes rebounded more quickly in patients treated with aminohydroxybutylidene diphosphonate, indicating that the loading amount (only 12.5 mg) used in this preliminary study is insufficient to sustain a prolonged effect. The effectiveness and lack of side effects render aminohydroxybutylidene diphosphonate an attractive treatment for malignant bone resorption.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Óseas/secundario , Ácido Clodrónico/uso terapéutico , Difosfonatos/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Alendronato , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/metabolismo , Calcio/sangre , Calcio/orina , Ensayos Clínicos como Asunto , Ácido Clodrónico/administración & dosificación , Difosfonatos/administración & dosificación , Femenino , Humanos , Hidroxiprolina/orina , Masculino , Persona de Mediana Edad , Dolor/tratamiento farmacológicoRESUMEN
Serum albumin levels were measured by electrophoresis in 552 evaluable patients with Hodgkin's disease. Determinations were made on all patients at onset, on 224 after induction therapy and on 78 in relapse after remissions of variable length. At onset a discrete hypoalbuminemia was evident, inversely related to stage and more marked in symptomatic cases and elder patients. Little or no differences in albumin levels were found with relation to histologic subtypes, sex and presence of weight loss or hepatic damage. Posttherapeutic normalization of serum albumin occurred only after achievement of complete remission and failed after partial remission, while a new clear decrease became evident in relapse. On the basis of 799 albumin measurements during active disease and in remission, the albumin/alpha 2-globulin ratio demonstrated a clear and useful clinical advantage over either albumin or alpha 2-globulin fractions alone as indicator of active disease and relapse. If defective synthesis is the most accepted mechanism for hypoalbuminemia in Hodgkin's disease, these results suggest a casual factor somehow related to the tumoral mass.
Asunto(s)
Enfermedad de Hodgkin/sangre , Albúmina Sérica/análisis , Adulto , Factores de Edad , alfa-Globulinas/análisis , Electroforesis en Acetato de Celulosa , Femenino , Humanos , MasculinoRESUMEN
A significant improvement of hyperinsulinemic diabetes was observed in a patient with Werner's syndrome after the removal of a large parasagittal meningioma. To our knowledge this is the second case reported in the literature. The possible relationship between meningioma and diabetes in Werner's syndrome is discussed.
Asunto(s)
Diabetes Mellitus Tipo 2/cirugía , Hiperinsulinismo/cirugía , Neoplasias Meníngeas/cirugía , Meningioma/cirugía , Síndrome de Werner/complicaciones , Glucemia/metabolismo , Péptido C/sangre , Diabetes Mellitus Tipo 2/sangre , Humanos , Hiperinsulinismo/sangre , Insulina/sangre , Masculino , Neoplasias Meníngeas/sangre , Meningioma/sangre , Persona de Mediana Edad , Síndrome de Werner/sangreRESUMEN
Pruritus was evaluated with respect to frequency, intensity, and prognostic significance in 360 patients with Hodgkin's disease. In order to discriminate severe from mild pruritus, the following criteria was used: (1) multiple excoriations; (2) ineffectiveness of local and systemic antipruritics; and (3) improvement with either radiotherapy or chemotherapy. Ninety of 360 patients had mild itching on admission and showed the same survival as the 249 nonitching cases; 21 patients presented with severe pruritus, which was also generalized, and showed a statistically shorter survival than that of mild and non-itching cases. This comparison was carried out between patients homologous with respect to sex, age, stage, A or B category, and histotype. Analysis of the data pointed out that the third requirement, i.e., improvement with antineoplastic therapy, is not substantial; moreover, for staging purposes, it is preferably replaced by the requisite of generalized pruritus. The intrinsically poor prognosis related to severe pruritus may be important for treatment, when this symptom occurs in early stages or without other systemic symptoms. The inclusion of severe pruritus among the Ann Arbor criteria for definition of the B-clinical category is proposed.